Published in Proteomics Weekly, November 7th, 2005
Researchers in Ireland reported, "CA125 is currently the most widely used tumor marker for ovarian epithelial cancer. The aim of the article by "M. J. Duffy and colleagues, St. Vincents Hospital, "was to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer."
"Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer," explained the scientists. "At present, therefore, CA125, either alone or in combination with other modalities, cannot be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.